{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:23:12Z","timestamp":1780053792848,"version":"3.54.0"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"Vol 37 No 11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,15]]},"DOI":"10.12788\/fp.0068","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T15:33:38Z","timestamp":1606836818000},"source":"Crossref","is-referenced-by-count":2,"title":["Continued Dosing of Oritavancin for Complicated Gram-Positive Infections"],"prefix":"10.12788","author":[{"given":"Susanne","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","published-online":{"date-parts":[[2020,11,15]]},"container-title":["Federal Practitioner"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/fdp03711502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T14:40:41Z","timestamp":1616164841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/fedprac\/article\/231522\/mixed-topics\/continued-dosing-oritavancin-complicated-gram-positive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,15]]},"references-count":0,"journal-issue":{"issue":"Vol 37 No 11","published-online":{"date-parts":[[2020,11,15]]},"published-print":{"date-parts":[[2020,11,15]]}},"URL":"https:\/\/doi.org\/10.12788\/fp.0068","relation":{},"subject":[],"published":{"date-parts":[[2020,11,15]]}}}